GlassScriptPhysician profile
Sergei Belkin
NPI 1083609762
$11,592.83
in general payments reported to CMS, 2019-2025
17 companies · $1,805 in 2025
The $1,805 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,559 · 2020: $527 · 2021: $2,154 · 2022: $1,868 · 2023: $1,350 · 2024: $1,331 · 2025: $1,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,485.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,490.77 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $1,795.89 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,505.03 | 2019-2021 | |
| Axsome Therapeutics, INC. | $1,138.66 | 2023-2025 | Auvelity |
| Lundbeck LLC | $785.36 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $738.97 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $732.77 | 2019-2025 | Rexulti |
| Neos Therapeutics, LP | $514.42 | 2021-2024 | Adzenys Xr-Odt |
| Abbvie INC. | $450.40 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $425.69 | 2019-2023 | Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $322.05 | 2019-2023 | Trintellix |
| Allergan, INC. | $192.24 | 2019 | |
| Supernus Pharmaceuticals, INC. | $167.04 | 2022-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $133.18 | 2024-2025 | Hetlioz, Fanapt |
| E.R. Squibb & Sons, L.L.C. | $113.27 | 2025 | Cobenfy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $59.09 | 2024-2025 | Dyanavel Xr |
| Indivior INC. | $28.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergei Belkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.